ABC | Volume 111, Nº2, August 2018

Review Article Leite et al Aspirin and hormonal therapy in breast cancer Arq Bras Cardiol. 2018; 111(2):205-212 This is an open-access article distributed under the terms of the Creative Commons Attribution License 49. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403-15. 50. AlgraAM,RothwellPM.Effectsofregularaspirinonlong-termcancerincidence andmetastasis:asystematiccomparisonofevidencefromobservationalstudies versus randomised trials. Lancet Oncol. 2012;13(5):518-27. 51. Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):239-42. 52. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, WarlowCP, Meade TW. Effect of daily aspirin on long-termrisk of death due to cancer: analysis of individual patient data from randomized trials. Lancet. 2011;377(9759):31-41. 53. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti- inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71-3.  54. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501-7. 55. Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, et al. Aspirin in the treatment of cancer: reductions inmetastatic spread and inmortality: a systematic review and meta-analyses of published studies. PLoS One. 2016;11(4):e0152402. 56. ChenWY, Holmes MD. Role of aspirin in breast câncer survival. Curr Oncol Rep. 2017;19(7):48. 212